NCT06400615View on ClinicalTrials.gov

Study That Tests AD109 in Patients Taking GLP-1 Drugs

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

December 26, 2024

Study Completion Date

December 26, 2024

Conditions
OSA
Interventions
DRUG

AD109

Oral administration at bedtime

Trial Locations (4)

28112

Monroe Biomedical Research, Monroe

32256

Clinical Neuroscience Solutions, Inc, Jacksonville

36207

Pinnacle Research Group, LLC, Anniston

38119

Clinical Neuroscience Solutions, Inc, Memphis

Sponsors

Lead Sponsor

Apnimed
All Listed Sponsors
lead

Apnimed

INDUSTRY

NCT06400615 - Study That Tests AD109 in Patients Taking GLP-1 Drugs | Biotech Hunter | Biotech Hunter